1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  

This page is powered by Blogger. Isn't yours?

Friday, March 31, 2017

 

Preventing Alzheimer’s: A Mind and Body Approach






















Mice with Alzheimer’s who are unable to produce the protein Ephexin5 have no memory problems, despite having brains littered with the amyloid beta protein that has been linked to the disease, a study reports.

The finding prompted Johns Hopkins University researchers to conclude that blocking the protein, which is found in excess in the brains of Alzheimer’s patients, may be a way to treat the disease.

It also may explain why levels of amyloid beta in the brain do not correlate with the severity of Alzheimer’s symptoms. Many scientists believe overproduction of amyloid beta is responsible for the development of the disease.

The study, “Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer’s-like impairment in mice,” was published in the Journal of Clinical Investigation.

“Ephexin5 is a tantalizing pharmaceutical target because, in otherwise healthy adults, there’s very little present in the brain,” Gabrielle L. Sell, a graduate student at the Johns Hopkins University School of Medicine, and first author of the study, said in a press release. “That means shutting off Ephexin5 should carry very few side effects.”

The research team started pondering Ephexin5’s role when other researchers showed that the brains of Alzheimer’s patients have high levels of a factor called EphB2.

EphB2 controls Ephexin5. Earlier research suggests EphB2 reduces the number of dendritic spines — or tiny protrusions of nerve cells — that scientists believe hold the majority of the synapses that disappear in Alzheimer’s. Synapses are involved in the transmission of nerve signals.

The team started by exploring the protein in lab-grown cells. Adding amyloid beta to lab-dish cells from healthy mice prompted the cells to produce Ephexin5. Researchers saw the same thing when they injected amyloid beta into the brains of healthy mice. Brains of deceased Alzheimer’s patients also contained higher levels of Ephexin5.

Researchers then turned to mouse models of Alzheimer’s that were engineered to produce excessive amounts of amyloid beta. The mice also had high Ephexin5 brain levels, along with the memory problems that characterize Alzheimer’s.

Up to that point, the evidence the team had collected indicated that the protein might be part of Alzheimer’s processes, but this did not prove that it causes cognitive decline.

To test the idea, the team manipulated Alzheimer’s mice — which produce plenty of amyloid beta — to deprive them of Ephexin5. They then tested the memory of healthy mice, Alzheimer’s mice, and Ephexin5-lacking Alzheimer’s mice.

They noted no differences in memory between mice lacking Ephexin5 and normal mice.

But since these mice lacked the protein from birth, researchers did another test. First they bred Alzheimer’s mice to adult age. This was intended to mirror the human scenario, in which patients typically accumulate amyloid beta for decades before memory symptoms start showing.

The team then used another molecular tool to shut down Ephexin5 production. They found that mice whose Ephexin5 was blocked at an older age did as well on memory tests as healthy mice.

“This study gives us some hope that moving beyond efforts to interrupt amyloid-beta pathways, and targeting pathways for synapse formation, will give us potent therapies for this devastating disease,” said Seth S. Margolis, PhD, assistant professor of biological chemistry and neuroscience, and the senior author of the study.

Story Source: The above story is based on materials provided by ALZHEIMERSNEWSTODAY
Note: Materials may be edited for content and length